Impact of oxaliplatin and trastuzumab combination therapy on tumor markers and T lymphocyte subsets for advanced gastric cancer

Table 2 Changes in serum tumor markers before and after treatment

Marker	Baseline	After treatment	P value
CEA (ng/mL)
Median (range)	15.2 (1.5-180.5)	6.1 (0.5-55.0)	< 0.001
CA19-9 (U/mL)
Median (range)	60.5 (10.5-1000.0)	26.4 (5.0-400.0)	< 0.001
CA72-4 (U/mL)
Median (range)	8.0 (1.5-300.0)	2.8 (0.5-80.0)	< 0.001

CEA: Carcinoembryonic antigen; CA19-9: Cancer antigen 19-9; CA72-4: Cancer antigen 72-4.